Group 1 - The company PACIFIC LEGEND (08547) plans to issue up to 82,107,900 shares at a price of HKD 0.468 per share, representing a premium of approximately 6.36% over the closing price of HKD 0.440 on the same day [1] - The maximum net proceeds from this placement are expected to be around HKD 38 million, which will be used for the company's working capital [1]

Group 1 - The company plans to issue 28.904 million new shares, representing approximately 8.3% of the enlarged share capital [1] - The subscription price is set at HKD 8.4 per share, which is a discount of 12.04% compared to the closing price of HKD 9.55 yesterday [1] - The total fundraising amount is expected to be HKD 243 million [1] Group 2 - Approximately 45% of the net proceeds from the placement will be allocated to preclinical research and clinical trials for localized fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [1] - Another 45% will be used for marketing activities, channel expansion, and brand building for CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam) [1] - About 10% of the proceeds will be utilized for working capital and other general corporate purposes [1]

Core Viewpoint - Jingtai Holdings (02228) announced a placement agreement to issue up to approximately 286 million placement shares at HKD 9.28 per share, aiming to raise approximately HKD 2.63 billion for various strategic initiatives [1] Group 1: Fundraising Details - The company plans to issue up to approximately 286 million shares through a placement agent [1] - Each placement share is priced at HKD 9.28, with total net proceeds expected to be around HKD 2.63 billion if fully subscribed [1] Group 2: Use of Proceeds - The raised funds will be utilized for continuous product iteration and upgrading, enhancing research and development capabilities, and solution capabilities [1] - The company aims to commercialize products and develop business by strengthening collaborations with external parties in similar and mutually beneficial industries [1] - Additional uses include potential acquisitions and investments, talent attraction and recruitment, working capital replenishment, and general corporate purposes [1]

Core Viewpoint - Crystal Tech Holdings (02228) announced a placement agreement to issue up to approximately 286 million shares at a price of HKD 9.28 per share, aiming to raise approximately HKD 2.63 billion for various strategic initiatives [1] Group 1: Fundraising Purpose - The net proceeds from the share placement are intended for continuous product iteration and upgrading, enhancing research and development capabilities, and solution capabilities [1] - The funds will also support product commercialization and business development, strengthening collaborations with external parties and partners in similar and mutually beneficial industries [1] - Additional uses of the funds include potential acquisitions and investments, talent attraction and recruitment, working capital replenishment, and general corporate purposes [1]

Core Viewpoint - The company, Guo'en Holdings (08121), has announced a placement agreement to issue up to 5 million shares at a price of HKD 0.60 per share, representing an approximate discount of 11.76% from the market price on the agreement date [1] Group 1: Placement Details - The placement will be conducted through a placement agent to no fewer than six independent third-party subscribers [1] - The estimated net proceeds from the placement are approximately HKD 2.7 million [1] Group 2: Use of Proceeds - The company intends to use the net proceeds entirely to support the development of its healthcare business, which includes hiring suitable talent, covering daily expenses of Shandong Guo'en, launching marketing activities, and developing sales platforms [1]

Core Viewpoint - Wu Xi Life (08148) plans to issue up to 25.45 million placement shares, representing approximately 6.3% of the company's enlarged issued share capital after the placement [1] Summary by Category Share Placement Details - The placement price is set at HKD 0.55 per share, which is a discount of approximately 19.12% compared to the closing price of HKD 0.68 on August 21 [1] - If all placement shares are fully subscribed, the net proceeds from the placement will be approximately HKD 13.5 million [1] Use of Proceeds - The company intends to use at least 70% of the net proceeds to expand its product sales business, with the remainder allocated for general working capital [1]

Core Viewpoint - The company, Guoen Holdings (08121), has announced a placement agreement to issue up to 5 million shares at a price of HKD 0.60 per share, representing an approximate discount of 11.76% from the closing price of HKD 0.680 on the date of the agreement [1] Group 1 - The placement is conditional and will be made to no less than six independent third-party investors [1] - The estimated net proceeds from the placement are approximately HKD 2.7 million [1] - The funds raised will be used to support the development of the company's healthcare business, including hiring suitable talent, covering daily expenses of Shandong Guoen, launching marketing activities, and developing sales platforms [1]

Group 1 - The company, Hansoh Pharmaceutical (03692), has entered into a placement agreement to issue 108 million shares at a price of HKD 36.30 per share, representing approximately 1.78% of the enlarged issued share capital post-placement [1] - The placement price of HKD 36.30 is approximately 6.49% lower than the closing price of HKD 38.82 on August 19, 2025 [1] Group 2 - The net proceeds from the placement, after deducting commissions, fees, and transaction costs, are estimated to be approximately HKD 3.897 billion, with a net price per share of about HKD 36.08 [2] - The company plans to allocate approximately 65% of the net proceeds for the research and development of new innovative drugs in areas such as oncology, autoimmune diseases, central nervous system, and metabolic diseases, as well as licensing innovative drugs and technology platforms [2] - Approximately 25% of the proceeds will be used for constructing new innovative drug production facilities and R&D laboratories, and upgrading existing R&D laboratories and production facilities [2] - The remaining 10% will be allocated for working capital and other general corporate purposes [2]

Core Viewpoint - The company, Gilead Sciences-B (01672), has entered into a placement and subscription agreement to sell and issue shares, which will result in a significant change in shareholding structure and raise funds for clinical trials and operational needs [1][2]. Group 1: Share Placement and Subscription Details - The total number of shares to be placed is 52.4 million, representing approximately 5.44% of the company's issued share capital as of the announcement date [2]. - The subscription involves 28.82 million new shares, accounting for about 2.90% of the enlarged issued share capital post-placement and subscription [2]. - The placement price is set at HKD 16.45 per share, which is a discount of approximately 9.9% compared to the closing price of HKD 18.26 on the last trading day [2]. Group 2: Shareholding Changes - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from approximately 53.38% to 49.45% of the issued share capital [2]. - The total shareholding percentage of the controlling shareholder will reduce from about 62.21% to approximately 58.03% after the issuance of the new shares [2]. Group 3: Use of Proceeds - The net proceeds from the subscription are expected to be around HKD 468 million after deducting commissions and estimated expenses [2]. - Approximately 90% of the net proceeds is intended for the development of clinical trials related to subcutaneous and oral peptide candidates for obesity [2]. - The remaining 10% of the net proceeds is suggested for working capital and other general corporate purposes [2].

Core Viewpoint - The company plans to place 5 million shares to TruMed at a price of HKD 20 per share, representing a discount of approximately 10.95% from the market price on August 15, 2025, which was HKD 22.46 [1] Group 1: Fundraising and Financial Impact - The expected net proceeds from the placement are approximately HKD 99 million [1] - About 60% of the net proceeds will be used to repay existing interest-bearing bank loans, which have increased due to additional borrowing for R&D expenses, leading to a rise in the company's debt-to-asset ratio [1] - The repayment of these loans is anticipated to strengthen the company's financial position, reduce interest-bearing debt ratio, and lower financial expenses [1] Group 2: Allocation of Proceeds - Approximately 30% of the net proceeds will be allocated for the development of new pipelines, including QX027N, QX031N, and QX035N [1] - About 10% of the proceeds will be used for working capital and other corporate purposes [1] Group 3: Investor Profile - TruMed is a fund primarily investing in healthcare stocks, controlled by Ting WANG [1]